Modular Medical Inc. Achieves Milestone with First Human Use of FDA-Cleared MODD1 Insulin Pump for Clinicians with Type 1 Diabetes
Modular Medical Inc. has announced a significant milestone with the first human use of its MODD1 insulin pump, receiving approval under the institutional review board from the United States Food and Drug Administration (FDA). The company plans to expand the deployment of MODD1 to a larger number of clinicians by mid-August, marking a critical step in advancing its user-friendly and affordable insulin delivery solution. Modular Medical aims to target the $3 billion adult "almost-pumpers" market with this innovative technology. Further updates on this development are anticipated as the company progresses with its clinical trials.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056718) on August 06, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。